{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:37:55Z","timestamp":1786552675003,"version":"build-2736575974"},"reference-count":198,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jncc.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:29:12Z","timestamp":1780399752000},"page":"329-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy"],"prefix":"10.1016","volume":"6","author":[{"given":"Hassan Abdelilah","family":"Tafenzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Essadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhizlane","family":"Belbaraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.jncc.2026.04.006_bib0001","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM199010043231403","article-title":"A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer","volume":"323","author":"Dillman","year":"1990","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jncc.2026.04.006_bib0002","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0003","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00595-019-1766-8","article-title":"Keys to successful induction chemoradiotherapy followed by surgery for stage III\/N2 non-small cell lung cancer","volume":"49","author":"Sata","year":"2019","journal-title":"Surg Today"},{"issue":"6","key":"10.1016\/j.jncc.2026.04.006_bib0004","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1378\/chest.123.6.2096","article-title":"Preoperative evaluation of patients undergoing lung resection surgery","volume":"123","author":"Datta","year":"2003","journal-title":"Chest"},{"issue":"34","key":"10.1016\/j.jncc.2026.04.006_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.14694\/EdBook_AM.2014.34.177","article-title":"50 years of progress in the systemic therapy of non-small cell lung cancer","author":"Wakelee","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"17","key":"10.1016\/j.jncc.2026.04.006_bib0006","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jncc.2026.04.006_bib0007","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0008","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jncc.2026.04.006_bib0009","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.006_bib0011","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jtho.2023.10.012","article-title":"The international association for the study of lung cancer staging project for lung cancer: proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer","volume":"19","author":"Huang","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"20","key":"10.1016\/j.jncc.2026.04.006_bib0012","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jncc.2026.04.006_bib0013","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jncc.2026.04.006_bib0014","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO-24-01324","article-title":"For the Management of Stage III NSCLC guideline expert panel. Management of stage III non-small cell lung cancer: ASCO guideline rapid recommendation update","volume":"42","author":"Daly","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102986","article-title":"Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2","volume":"9","author":"Bradley","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jncc.2026.04.006_bib0016","article-title":"CheckMate 73L: phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N \u00b1 ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage III NSCLC","volume":"24","author":"Peters","year":"2024","journal-title":"Immuno-Oncol Technol"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0017","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jncc.2026.04.006_bib0018","doi-asserted-by":"crossref","first-page":"S1624","DOI":"10.1016\/j.annonc.2024.10.643","article-title":"PACIFIC-5: a phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)","volume":"35","author":"Wu","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0019","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-025-01768-1","article-title":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","volume":"18","author":"Wu","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jncc.2026.04.006_bib0020","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8609","article-title":"Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)","volume":"41","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.jncc.2026.04.006_bib0022","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18440","article-title":"Durvalumab alone or combined with novel agents for unresectable stage III non-small cell lung cancer: update from the COAST randomized clinical trial","volume":"8","author":"Aggarwal","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0024","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2026.04.006_bib0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0026","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1200\/JCO.2022.40.16_suppl.8508","article-title":"Two-year update from KEYNOTE-799: pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0027","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2022.10.006","article-title":"Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: the phase II DETERRED trial","volume":"174","author":"Liu","year":"2022","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0028","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"Peters","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010316","volume":"13","author":"Durm","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"17_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0030","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8512","volume":"39","author":"Jabbour","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.006_bib0032","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","volume":"23","author":"Ruysscher","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jncc.2026.04.006_bib0033","doi-asserted-by":"crossref","first-page":"S990","DOI":"10.1016\/j.annonc.2022.07.1095","article-title":"Randomized, phase III study of MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by MK-7684A vs cCRT followed by durvalumab for unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYVIBE-006","volume":"33","author":"Jabbour","year":"2022","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8584","article-title":"Randomized phase III trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: a trial of the ECOG-ACRIN Cancer Research Group (EA5181)","volume":"39","author":"Varlotto","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0035","article-title":"Concurrent versus sequential immunotherapy with chemoradiotherapy for unresectable stage III non-small-cell lung cancer: a retrospective study","volume":"14","author":"Meng-Xi","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0036","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13014-025-02616-9","article-title":"Efficacy and safety of induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced non-small cell lung cancer: a retrospective study","volume":"20","author":"Liu","year":"2025","journal-title":"Radiat Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0037","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/cancers17101711","article-title":"Early immune checkpoint inhibitor administration increases the risk of radiation-induced pneumonitis in patients with stage III unresectable NSCLC undergoing chemoradiotherapy","volume":"17","author":"Qin","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.jncc.2026.04.006_bib0038","article-title":"Concurrent versus sequential immunotherapy with chemoradiotherapy for unresectable stage III non-small-cell lung cancer: a retrospective study","volume":"14","author":"Meng-Xi","year":"2024","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0039","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1007\/s00432-023-04654-w","article-title":"Concurrent\/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study","volume":"149","author":"K\u00e4smann","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"13","key":"10.1016\/j.jncc.2026.04.006_bib0040","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.3390\/cancers16132338","article-title":"Identification and application of emerging biomarkers in treatment of non-small-cell lung cancer: systematic review","volume":"16","author":"Restrepo","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0041","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"6230","key":"10.1016\/j.jncc.2026.04.006_bib0042","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0043","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0044","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.006_bib0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2026.04.006_bib0046","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","article-title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","volume":"28","author":"Peters","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.49591","article-title":"Analysis of tumor mutational burden, progression-free survival, and local-regional control in patients with locally advanced non-small cell lung cancer treated with chemoradiation and durvalumab","volume":"6","author":"Lebow","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jncc.2026.04.006_bib0048","doi-asserted-by":"crossref","first-page":"ii48","DOI":"10.1093\/annonc\/mdz063.016","article-title":"Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: secondary analysis of the OAK and POPLAR randomized clinical trials","volume":"30","author":"Nie","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0049","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12916-022-02360-x","article-title":"ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors","volume":"20","author":"Nie","year":"2022","journal-title":"BMC Med"},{"issue":"7655","key":"10.1016\/j.jncc.2026.04.006_bib0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"issue":"403","key":"10.1016\/j.jncc.2026.04.006_bib0051","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0052","doi-asserted-by":"crossref","first-page":"oyae344","DOI":"10.1093\/oncolo\/oyae344","article-title":"Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"30","author":"Leite da Silva","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.jncc.2026.04.006_bib0053","doi-asserted-by":"crossref","DOI":"10.21037\/actr-24-201","article-title":"Emerging role of circulating tumor DNA as a predictive biomarker in consolidation immunotherapy for unresectable stage III NSCLC","volume":"3","author":"Huisman","year":"2025","journal-title":"AME Clin Trials Rev"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0054","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2025.43.16_suppl.8011","article-title":"ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab","volume":"43","author":"Horndalsveen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.006_bib0055","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/PO.21.00182","article-title":"Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors","author":"Weber","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0056","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jtho.2024.06.024","article-title":"Analysis of circulating tumor DNA predicts outcomes of short-course consolidation immunotherapy in unresectable stage III NSCLC","volume":"19","author":"Jun","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2026.04.006_bib0057","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/1078-0432.CCR-24-3612","article-title":"ctDNA clearance as an early indicator of improved clinical outcomes in advanced NSCLC treated with TKI: findings from an aggregate analysis of eight clinical trials","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2026.04.006_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105109","article-title":"Circulating tumour DNA-based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis","volume":"103","author":"Zheng","year":"2024","journal-title":"EBioMedicine"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0059","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.2025.43.16_suppl.3142","article-title":"Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors","volume":"43","author":"Schwartz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annonc.2023.11.008","article-title":"Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer","volume":"35","author":"Tran","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0061","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1200\/JCO.2024.42.16_suppl.8078","article-title":"Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)","volume":"42","author":"Goldstein","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jncc.2026.04.006_bib0062","article-title":"Evaluating circulating tumor DNA clearance as an early intermediate end point predicting clinical benefit in metastatic nonsquamous NSCLC after first-line chemoimmunotherapy","volume":"6","author":"Yuan","year":"2025","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0063","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","article-title":"Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients","volume":"41","author":"Pan","year":"2023","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.jncc.2026.04.006_bib0064","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1158\/2159-8290.CD-24-1704","article-title":"Integrating ctDNA analysis and radiomics for dynamic risk assessment in localized lung cancer","volume":"15","author":"Moding","year":"2025","journal-title":"Cancer Discov"},{"issue":"25","key":"10.1016\/j.jncc.2026.04.006_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.10.020","article-title":"Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction","volume":"188","author":"Black","year":"2025","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0066","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41698-025-00991-w","article-title":"Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction","volume":"9","author":"Sisoudiya","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"10.1016\/j.jncc.2026.04.006_bib0067","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.trecan.2023.08.011","article-title":"Variant allele frequency: a decision-making tool in precision oncology?","volume":"9","author":"Boscolo Bielo","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0068","article-title":"Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases","volume":"6","author":"Alder","year":"2024","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.jncc.2026.04.006_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1409383","article-title":"Applications of cerebrospinal fluid circulating tumor cells and circulating tumor-derived DNA in diagnosis, prognosis, and personalized treatment of CNS metastases","volume":"14","author":"Pentsova","year":"2024","journal-title":"Front Oncol"},{"issue":"7741","key":"10.1016\/j.jncc.2026.04.006_bib0070","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0071","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/j.jtho.2024.09.612","article-title":"PLATINUM trial: preliminary analysis of lazertinib therapy in locally advanced, unresectable, EGFR mutation(+) NSCLC following CCRT","volume":"19","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0072","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oncolo\/oyae107","article-title":"The ASCENT trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC","volume":"29","author":"Chang","year":"2024","journal-title":"Oncologist"},{"issue":"7878","key":"10.1016\/j.jncc.2026.04.006_bib0073","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0074","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61087-2","article-title":"Novel therapeutic strategies for rare mutations in non-small cell lung cancer","volume":"14","author":"Gou","year":"2024","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.jncc.2026.04.006_bib0075","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1074\/jbc.RA118.006336","article-title":"An unbiased in vitro screen for activating epidermal growth factor receptor mutations","volume":"294","author":"Chakroborty","year":"2019","journal-title":"J Biol Chem"},{"issue":"416","key":"10.1016\/j.jncc.2026.04.006_bib0076","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan6566","article-title":"A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer","volume":"9","author":"Kohsaka","year":"2017","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0077","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/s41467-024-45594-4","article-title":"Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants","volume":"15","author":"Hayes","year":"2024","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0078","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-a systematic review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0079","doi-asserted-by":"crossref","first-page":"S1587","DOI":"10.1016\/j.annonc.2022.10.411","article-title":"Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: cohort 2","volume":"33","author":"Fang","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0080","doi-asserted-by":"crossref","first-page":"S1695","DOI":"10.1016\/j.annonc.2023.10.652","article-title":"Efficacy and safety of dacomitinib in treatment-na\u00efve patients with advanced NSCLC harboring uncommon EGFR mutations","volume":"34","author":"Wu","year":"2023","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0081","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2024.42.16_suppl.8512","article-title":"Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: updated analysis from the international CodeBreaK 101 trial","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0082","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8653","article-title":"Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)","volume":"42","author":"Barlesi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2026.04.006_bib0083","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0084","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jncc.2026.04.006_bib0085","doi-asserted-by":"crossref","first-page":"S1303","DOI":"10.1016\/j.annonc.2023.10.059","article-title":"Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"34","author":"Loong","year":"2023","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.jncc.2026.04.006_bib0086","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.jncc.2026.04.006_bib0087","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.24.00724","article-title":"CNS protective effect of selpercatinib in first-line RET fusion-positive advanced non-small cell lung cancer","volume":"42","author":"P\u00e9rol","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108367","article-title":"HORIZON-01: a phase I-III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC)","volume":"200","author":"Popat","year":"2025","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.jncc.2026.04.006_bib0089","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1016\/j.jtho.2023.09.511","article-title":"NAUTIKA1 study: preliminary efficacy and safety data with neoadjuvant alectinib in patients with stage IB-III ALK+ NSCLC","volume":"18","author":"Lee","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jtho.2024.09.1379","article-title":"Consolidation ALK tyrosine kinase inhibitors versus durvalumab or observation after chemoradiation in unresectable stage III ALK-positive NSCLC","volume":"20","author":"Nassar","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0091","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225036","article-title":"Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"10454","key":"10.1016\/j.jncc.2026.04.006_bib0092","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"issue":"8056","key":"10.1016\/j.jncc.2026.04.006_bib0093","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","article-title":"Clonal driver neoantigen loss under EGFR TKI and immune selection pressures","volume":"639","author":"Al Bakir","year":"2025","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.006_bib0094","doi-asserted-by":"crossref","first-page":"710","DOI":"10.21037\/tlcr.2019.06.02","article-title":"Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?","volume":"8","author":"Bruno","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jncc.2026.04.006_bib0095","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225036","article-title":"Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2026.04.006_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105123","article-title":"Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA","volume":"10","author":"Carbone","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0097","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41392-025-02473-8","article-title":"Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges","volume":"10","author":"Choucair","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0098","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.immuni.2023.09.004","article-title":"Cancer cell-intrinsic mechanisms driving acquired immune tolerance","volume":"56","author":"Ghorani","year":"2023","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.006_bib0099","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.jncc.2026.04.006_bib0100","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1158\/1078-0432.CCR-22-0741","article-title":"Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)","volume":"28","author":"Mack","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.jncc.2026.04.006_bib0101","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; exploratory analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0102","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-73749-2","article-title":"Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with icotinib: phase 2 multicenter trial result","volume":"14","author":"Hong","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jncc.2026.04.006_bib0103","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jtho.2024.07.008","article-title":"Longitudinal analyses of circulating tumor DNA for the detection of EGFR mutation-positive advanced NSCLC progression during treatment: data from FLAURA and AURA3","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.006_bib0104","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0105","first-page":"S1052","article-title":"Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC","volume":"36","author":"Aperribay","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0106","doi-asserted-by":"crossref","first-page":"S784","DOI":"10.1016\/j.annonc.2023.09.2397","article-title":"ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)","volume":"34","author":"Yang","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2026.04.006_bib0107","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0108","doi-asserted-by":"crossref","first-page":"366","DOI":"10.21037\/tlcr.2020.02.07","article-title":"Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report","volume":"9","author":"S\u00e1nchez-Herrero","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jncc.2026.04.006_bib0109","doi-asserted-by":"crossref","first-page":"S1294","DOI":"10.1016\/j.annonc.2023.10.049","article-title":"An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer","volume":"34","author":"Black","year":"2023","journal-title":"Ann Oncol"},{"issue":"7957","key":"10.1016\/j.jncc.2026.04.006_bib0110","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jncc.2026.04.006_bib0111","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ccell.2025.07.008","article-title":"Circulating tumor cells: blood-based detection, molecular biology, and clinical applications","volume":"43","author":"Dai","year":"2025","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0112","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","article-title":"MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies","volume":"55","author":"Kim","year":"2023","journal-title":"Exp Mol Med"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0113","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0114","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41467-024-55594-z","article-title":"Integrated multiomics signatures to optimize the accurate diagnosis of lung cancer","volume":"16","author":"Zhao","year":"2025","journal-title":"Nat Commun"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0115","article-title":"Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC)","volume":"42","author":"Oughton","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0116","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: a proof-of-concept, phase 2 trial","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.006_bib0117","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41416-022-01893-5","article-title":"Repositioning canakinumab for non-small cell lung cancer\u2014important lessons for drug repurposing in oncology","volume":"127","author":"Lythgoe","year":"2022","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0118","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.23.00910","article-title":"Canakinumab as adjuvant therapy in patients with completely resected non-small-cell lung cancer: results from the CANOPY-A double-blind, randomized clinical trial","volume":"42","author":"Garon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107451","volume":"189","author":"Paz-Ares","year":"2024","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0120","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S1556-0864(23)00387-8","article-title":"Boosting immune response with copanlisib in locally advanced unresectable non-small cell lung cancer starting durvalumab consolidation: a phase Ib study","volume":"18","author":"Hao","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0121","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1200\/JCO.2024.42.16_suppl.8065","article-title":"A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab \u00b1 bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086)","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0122","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jncc.2026.04.006_bib0123","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO.22.01035","article-title":"Lung-MAP: a collaborative roadmap to improve cancer outcomes","volume":"40","author":"Leal","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jncc.2026.04.006_bib0124","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S1470-2045(20)30475-7","article-title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","volume":"21","author":"Redman","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jncc.2026.04.006_bib0125","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.78.8.5147","article-title":"Human trophoblast cell-surface antigens defined by monoclonal antibodies","volume":"78","author":"Lipinski","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"issue":"48","key":"10.1016\/j.jncc.2026.04.006_bib0126","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0127","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321555","article-title":"Trop-2 expression in non-small cell lung cancer","volume":"20","author":"Kuo","year":"2025","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.006_bib0129","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1556-0864(25)00317-X","article-title":"TROPION-Lung10: phase III study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig in non-squamous (NSQ) advanced\/metastatic (a\/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)","volume":"20","author":"Newsom-Davis","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0130","first-page":"1","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","author":"Cascone","year":"2025","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0131","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8647","article-title":"TROPION-Lung14: a phase 3 study of osimertinib \u00b1 datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA\/M) non-small cell lung cancer (NSCLC)","volume":"43","author":"Lu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0132","doi-asserted-by":"crossref","first-page":"S848","DOI":"10.1016\/j.annonc.2023.09.2538","volume":"34","author":"Planchard","year":"2023","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0133","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2023.41.16_suppl.9004","article-title":"TROPION-Lung02: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC)","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0134","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.006_bib0135","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1556-0864(25)00319-3","volume":"20","author":"Nadal","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"31","key":"10.1016\/j.jncc.2026.04.006_bib0136","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0137","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.006_bib0138","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0139","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf225","article-title":"Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management","author":"Lisberg","year":"2025","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"Kontermann RE. The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.006_bib0141","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-472792","article-title":"Bispecific antibodies in non-small cell lung cancer: from targeted innovation to real-world integration","volume":"45","author":"Carlisle","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0142","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41571-025-01024-y","article-title":"The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab","volume":"22","author":"Herbst","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.006_bib0143","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/ph16101461","article-title":"Bispecific antibodies in lung cancer: a state-of-the-art review","volume":"16","author":"Khosla","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0144","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8604","volume":"41","author":"Guisier","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.006_bib0145","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0146","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1200\/JCO.2024.42.16_suppl.2533","article-title":"Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): initial results of a randomized, open-label, phase 2 trial","volume":"42","author":"Aerts","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0147","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jncc.2026.04.006_bib0148","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"issue":"30","key":"10.1016\/j.jncc.2026.04.006_bib0149","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202501819","article-title":"Bispecific antibody targeting VEGF\/TGF-\u03b2 synergizes with local radiotherapy: turning tumors from cold to inflamed and amplifying abscopal effects","volume":"12","author":"Lyu","year":"2025","journal-title":"Adv Sci"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-025-01678-2","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis","volume":"18","author":"Wu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0151","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cac2.70051","article-title":"Stereotactic body radiotherapy plus cadonilimab (PD-1\/CTLA-4 bispecific antibody) as third-line or beyond therapy for refractory solid tumors: a phase 1b study","volume":"45","author":"Xiao","year":"2025","journal-title":"Cancer Commun"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0152","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2026.04.006_bib0153","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","article-title":"Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors","volume":"28","author":"Gu","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0154","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Claus","year":"2023","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB immunotherapy: advances and hurdles","volume":"56","author":"Singh","year":"2024","journal-title":"Exp Mol Med"},{"issue":"18","key":"10.1016\/j.jncc.2026.04.006_bib0156","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jama.1933.02740430017005","article-title":"Successful removal of an entire lung for carcinoma of the bronchus","volume":"101","author":"Graham","year":"1933","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0157","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1183\/09031936.00143112","article-title":"Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer","volume":"42","author":"Huber","year":"2013","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0158","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1245\/s10434-025-17327-4","article-title":"Updates on the version 9 American joint committee on cancer staging system for lung cancer","volume":"32","author":"Asamura","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.006_bib0159","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.ejso.2021.01.002","article-title":"Uptake and survival effects of minimally invasive surgery for lung cancer: a population-based study","volume":"47","author":"Akhtar-Danseh","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0160","article-title":"Prediction of postoperative pulmonary complications using preoperative controlling nutritional status (CONUT) score in patients with resectable non-small cell lung cancer","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"issue":"9687","key":"10.1016\/j.jncc.2026.04.006_bib0161","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0162","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3816\/CLC.2000.n.020","article-title":"Randomized trial of surgery versus radiotherapy in patients with stage IIIA (N2) non-small-cell lung cancer after a response to induction chemotherapy: EORTC 08941","volume":"2","author":"Splinter","year":"2000","journal-title":"Clin Lung Cancer"},{"issue":"35","key":"10.1016\/j.jncc.2026.04.006_bib0163","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2015.62.6812","article-title":"Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE)","volume":"33","author":"Eberhardt","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0164","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.athoracsur.2020.04.035","article-title":"Salvage lung resections after definitive chemoradiotherapy: a safe and effective oncologic option","volume":"110","author":"Bograd","year":"2020","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0165","article-title":"Salvage surgery is safe and effective for clinical stage III non-small-cell lung cancer","volume":"40","author":"Luo","year":"2025","journal-title":"Interdiscip Cardiovasc Thorac Surg"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0166","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12916-022-02696-4","article-title":"Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial","volume":"20","author":"Zhu","year":"2022","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0167","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-024-01861-w","article-title":"Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0168","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1038\/s41467-025-58435-9","article-title":"Neoadjuvant aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial","volume":"16","author":"Bian","year":"2025","journal-title":"Nat Commun"},{"issue":"171","key":"10.1016\/j.jncc.2026.04.006_bib0169","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0195-2023","article-title":"Resectable non-stage IV nonsmall cell lung cancer: the surgical perspective","volume":"33","author":"Aigner","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"12","key":"10.1016\/j.jncc.2026.04.006_bib0170","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.3390\/cancers16122281","article-title":"Functional and disability outcomes in NSCLC patients post-lobectomy undergoing pulmonary rehabilitation: a biopsychosocial approach","volume":"16","author":"Zawadzka-Fabijan","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0171","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-019-0624-7","article-title":"The role of surgery in management of locally advanced non-small cell lung cancer","volume":"20","author":"Bryan","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0172","first-page":"249","article-title":"NCCN guidelines index NSCLC table of contents discussion","volume":"22","author":"Ettinger","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0173","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae008","article-title":"Upfront surgery for stage IIIA\/B non-small cell lung cancer: retrospective cohort study","volume":"8","author":"Deng","year":"2024","journal-title":"BJS Open"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0174","doi-asserted-by":"crossref","first-page":"555","DOI":"10.21037\/tlcr-20-453","article-title":"Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer","volume":"10","author":"Hamada","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1470-2045(24)00680-6","article-title":"Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?","volume":"26","author":"Pechoux","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.006_bib0176","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoncol.2023.6033","article-title":"Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non-small cell lung cancer: a nonrandomized controlled trial","volume":"10","author":"Wu","year":"2024","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2026.04.006_bib0177","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jtho.2017.07.036","article-title":"Concomitant chemotherapy and radiotherapy with SBRT boost for unresectable stage III non-small cell lung cancer: a phase I study","volume":"12","author":"Higgins","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0178","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102573","article-title":"Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: a systematic review","volume":"118","author":"Allignet","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"24","key":"10.1016\/j.jncc.2026.04.006_bib0179","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.3390\/cancers16244233","article-title":"Updates in management of unresectable stage III non-small cell lung cancer: a radiation oncology perspective","volume":"16","author":"Narra","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0180","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.athoracsur.2022.07.053","article-title":"Hospital utilization of stereotactic body radiation therapy and rates of surgical refusal","volume":"115","author":"Till","year":"2023","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.006_bib0181","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/OP.22.00475","article-title":"Stereotactic body radiotherapy for the management of early-stage non-small-cell lung cancer: a clinical overview","volume":"19","author":"Buchberger","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jncc.2026.04.006_bib0182","article-title":"MDT-BRIDGE: a phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC","volume":"20","author":"Reck","year":"2023","journal-title":"Immuno-Oncol Technol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.04.006_bib0183","doi-asserted-by":"crossref","first-page":"8082","DOI":"10.1200\/JCO.2024.42.16_suppl.8082","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial","volume":"42","author":"Wu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0184","doi-asserted-by":"crossref","first-page":"S1394","DOI":"10.1016\/j.annonc.2024.07.475","article-title":"A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer","volume":"35","author":"Hsieh","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jncc.2026.04.006_bib0185","article-title":"Supporting dose decisions for antibody drug conjugates (ADC) through combined efficacy and toxicity modeling","volume":"11","author":"Singh","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0186","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41523-022-00393-2","article-title":"Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings","volume":"8","author":"Hsieh","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.006_bib0187","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13938","article-title":"International cost-effectiveness analysis of durvalumab in stage III non-small cell lung cancer","volume":"7","author":"Kareff","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.006_bib0188","doi-asserted-by":"crossref","first-page":"153","DOI":"10.6004\/jnccn.2020.7621","article-title":"Cost-effectiveness of durvalumab after chemoradiotherapy in unresectable stage III NSCLC: a US healthcare perspective","volume":"19","author":"Mehra","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jncc.2026.04.006_bib0189","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109589","article-title":"Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer","volume":"114","author":"Shu","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"14","key":"10.1016\/j.jncc.2026.04.006_bib0190","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2217\/imt-2020-0112","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC","volume":"12","author":"Li","year":"2020","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.jncc.2026.04.006_bib0191","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.clinthera.2025.07.002","article-title":"Cost-effectiveness of perioperative nivolumab for stage III non-small-cell lung cancer: a perspective from the United States","volume":"47","author":"Sun","year":"2025","journal-title":"Clin Ther"},{"issue":"16","key":"10.1016\/j.jncc.2026.04.006_bib0192","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70083","article-title":"Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer","volume":"13","author":"Tian","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.jncc.2026.04.006_bib0193","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231169983","article-title":"Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer","volume":"15","author":"Yang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jncc.2026.04.006_bib0194","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102902","article-title":"Antibody-drug conjugates in NSCLC with actionable genomic alterations: optimizing smart delivery of chemotherapy to the target","volume":"134","author":"Mountzios","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"20","key":"10.1016\/j.jncc.2026.04.006_bib0195","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000042419","article-title":"Cost-effectiveness of datopotamab deruxtecan in previously treated advanced nonsquamous NSCLC","volume":"104","author":"Song","year":"2025","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.006_bib0196","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.annonc.2020.01.007","article-title":"A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland","volume":"31","author":"Panje","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.006_bib0197","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-020-01069-z","article-title":"The current treatment landscape in the UK for stage III NSCLC","volume":"123","author":"Evison","year":"2020","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.006_bib0198","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.radonc.2018.04.013","article-title":"Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non-small cell lung cancer","volume":"128","author":"Paix","year":"2018","journal-title":"Radiother Oncol"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005426000657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005426000657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:46:39Z","timestamp":1786549599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667005426000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":198,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2667005426000657"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2026.04.006","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}